- Home
- REAL vs AVIR Comparison
REAL vs AVIR Comparison
Compare REAL & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REAL
- AVIR
- Stock Information
- Founded
- REAL 2011
- AVIR 2012
- Country
- REAL United States
- AVIR United States
- Employees
- REAL N/A
- AVIR N/A
- Industry
- REAL Other Specialty Stores
- AVIR Medicinal Chemicals and Botanical Products
- Sector
- REAL Consumer Discretionary
- AVIR Health Care
- Exchange
- REAL Nasdaq
- AVIR Nasdaq
- Market Cap
- REAL 641.9M
- AVIR 273.0M
- IPO Year
- REAL 2019
- AVIR 2020
- Fundamental
- Price
- REAL $5.29
- AVIR $3.76
- Analyst Decision
- REAL Buy
- AVIR Hold
- Analyst Count
- REAL 5
- AVIR 1
- Target Price
- REAL $8.40
- AVIR $6.00
- AVG Volume (30 Days)
- REAL 2.5M
- AVIR 397.2K
- Earning Date
- REAL 08-05-2025
- AVIR 08-06-2025
- Dividend Yield
- REAL N/A
- AVIR N/A
- EPS Growth
- REAL N/A
- AVIR N/A
- EPS
- REAL N/A
- AVIR N/A
- Revenue
- REAL $616,717,000.00
- AVIR N/A
- Revenue This Year
- REAL $11.70
- AVIR N/A
- Revenue Next Year
- REAL $10.10
- AVIR N/A
- P/E Ratio
- REAL N/A
- AVIR N/A
- Revenue Growth
- REAL 11.89
- AVIR N/A
- 52 Week Low
- REAL $2.24
- AVIR $2.46
- 52 Week High
- REAL $11.38
- AVIR $4.15
- Technical
- Relative Strength Index (RSI)
- REAL 50.55
- AVIR 68.22
- Support Level
- REAL $5.17
- AVIR $3.63
- Resistance Level
- REAL $5.56
- AVIR $3.83
- Average True Range (ATR)
- REAL 0.24
- AVIR 0.14
- MACD
- REAL 0.06
- AVIR 0.01
- Stochastic Oscillator
- REAL 67.84
- AVIR 87.00
About REAL The RealReal Inc.
The RealReal is the largest pure-play luxury resale platform in the US, generating $1.8 billion in 2024 gross merchandise volume and addressing a niche (personal luxury resale) that had previously been serviced by inefficient upscale boutiques and local pawn shops. The company generates revenue via consignment and first-party sales on its online marketplace, and through a small volume of direct sales. With a hands-on approach that actively sources inventory and authenticates every item on its platform, The RealReal is able to justify much higher take rates than peers, working out to roughly 36% of net merchandise value in 2024, which excludes returns, cancellations, and first-party sales.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).